Clinical Focus

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Savolitinib Plus Osimertinib Improves PFS, OS in MET-Driven NSCLC

FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma

FDA Grants Type C Meeting for OST-HER2 OS Data in Osteosarcoma

Study Finds Persistent Breast Cancer Survival Edge in Asian American Women

VA Study Finds Potential OS Benefit for Enzalutamide in Older mCSPC Patients